Evidence map›Paper›PMID 19052197›Full record

Trial reportThe Journal of neuroscience : the official journal of the Society for Neuroscience2008

A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety.

Tomas Furmark, Lieuwe Appel, Susanne Henningsson, Fredrik Ahs, Vanda Faria, Clas Linnman, Anna Pissiota, Orjan Frans, Massimo Bani, Paolo Bettica and 7 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 5 pooled it
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 5 syntheses or guidelines pooled it, 209 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Network modulation following sham surgery in Parkinson's disease.The Journal of clinical investigation · 2014
    Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Placebo: a brief updated review.Naunyn-Schmiedeberg's archives of pharmacology · 2022
    Review
  19. Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 3 countries.

Tomas FurmarkDepartment of Psychology, Uppsala University, Uppsala, Sweden. tomas.furmark@psyk.uu.se
Lieuwe Appel
Susanne Henningsson
Fredrik Ahs
Vanda Faria
Clas Linnman
Anna Pissiota
Orjan Frans
Massimo Bani
Paolo Bettica
Emilio Merlo Pich
Eva Jacobsson
Kurt Wahlstedt
Lars Oreland
Bengt Långström
Elias Eriksson
Mats Fredrikson
Uppsala University · SEGlaxoSmithKline (Italy) · ITAalborg University · DKTrelleborg (Sweden) · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Placebo may yield beneficial effects that are indistinguishable from those of active medication, but the factors underlying proneness to respond to placebo are widely unknown. Here, we used functional neuroimaging to examine neural correlates of anxiety reduction resulting from sustained placebo treatment under randomized double-blind conditions, in patients with social anxiety disorder. Brain activity was assessed during a stressful public speaking task by means of positron emission tomography before and after an 8 week treatment period. Patients were genotyped with respect to the serotonin transporter-linked polymorphic region (5-HTTLPR) and the G-703T polymorphism in the tryptophan hydroxylase-2 (TPH2) gene promoter. Results showed that placebo response was accompanied by reduced stress-related activity in the amygdala, a brain region crucial for emotional processing. However, attenuated amygdala activity was demonstrable only in subjects who were homozygous for the long allele of the 5-HTTLPR or the G variant of the TPH2 G-703T polymorphism, and not in carriers of short or T alleles. Moreover, the TPH2 polymorphism was a significant predictor of clinical placebo response, homozygosity for the G allele being associated with greater improvement in anxiety symptoms. Path analysis supported that the genetic effect on symptomatic improvement with placebo is mediated by its effect on amygdala activity. Hence, our study shows, for the first time, evidence of a link between genetically controlled serotonergic modulation of amygdala activity and placebo-induced anxiety relief.

Indexed as

AdultAmygdalaAnxiety DisordersDNA Mutational AnalysisDouble-Blind MethodFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic TestingGenotypeHumansMaleMiddle AgedNeuropsychological TestsPlacebo EffectPolymorphism, GeneticSerotoninSerotonin Plasma Membrane Transport ProteinsTryptophan Hydroxylase

Identifiers

PMID19052197
PMCPMC6671592
OpenAlexW2161011520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.